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Abstract
Background: Many cancers, including breast cancer, have been identified with increased levels of phosphorylated
or the active form of Signal Transducers and Activators of Transcription 3 (STAT3) protein. However, whether
the tumor microenvironment plays a role in this activation is still poorly understood.
Methods: Conditioned media, which contains soluble factors from MDA-MB-231 and MDA-MB-468 breast
cancer cells and breast cancer associated fibroblasts, was added to MCF-10A breast epithelial and MDA-MB-453
breast cancer cells. The stimulation of phosphorylated STAT3 (p-STAT3) levels by conditioned media was assayed
by Western blot in the presence or absence of neutralized IL-6 antibody, or a JAK/STAT3 inhibitor, JSI-124. The
stimulation of cell proliferation in MCF-10A cells by conditioned media in the presence or absence of JSI-124 was
subjected to MTT analysis. IL-6, IL-10, and VEGF levels were determined by ELISA analysis.
Results: Our results demonstrated that conditioned media from cell lines with constitutively active STAT3 are
sufficient to induce p-STAT3 levels in various recipients that do not possess elevated p-STAT3 levels. This
signaling occurs through the JAK/STAT3 pathway, leading to STAT3 phosphorylation as early as 30 minutes and
is persistent for at least 24 hours. ELISA analysis confirmed a correlation between elevated levels of IL-6
production and p-STAT3. Neutralization of the IL-6 ligand or gp130 was sufficient to block increased levels of p-
STAT3 (Y705) in treated cells. Furthermore, soluble factors within the MDA-MB-231 conditioned media were
also sufficient to stimulate an increase in IL-6 production from MCF-10A cells.
Conclusion: These results demonstrate STAT3 phosphorylation in breast epithelial cells can be stimulated by
paracrine signaling through soluble factors from both breast cancer cells and breast cancer associated fibroblasts
with elevated STAT3 phosphorylation. The induction of STAT3 phosphorylation is through the IL-6/JAK pathway
and appears to be associated with cell proliferation. Understanding how IL-6 and other soluble factors may lead
to STAT3 activation via the tumor microenvironment will provide new therapeutic regimens for breast
carcinomas and other cancers with elevated p-STAT3 levels.
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Background
After heart disease and lung cancer, breast cancer ranks as
the third leading cause of death in women in the United
States, accounting for over 40,000 mortalities in 2006 [1].
Moreover, the American Cancer Society estimates that
around 178,000 invasive breast cancer cases will be found
in 2007 [1]. Much advancement has been made in breast
cancer treatment, including the characterization of breast
disease based on the patient's hormone receptor status,
understanding the role of inherited genetic abnormalities,
and the assessment of the risk for invasive disease [2,3].
Moreover, understanding the molecular basis for each
patient's disease has allowed for more effective treatment.
Although mortality rates are declining, it is clear that with
over 40,000 deaths each year there is still much to learn
about the disease and how to best increase each patient's
chance for survival. There are still many poorly under-
stood molecular factors which increase breast tumorigen-
esis. Among these are the Signal Transducers and
Activators of Transcription (STAT) proteins. Constitutive
activation of STAT proteins is found in an astounding
number of breast cancers and other human diseases [4-6].
It is clear that we need to understand the role of STAT pro-
teins in order to find more effective and personalized
treatments for breast cancer patients.
STAT proteins constitute a family of transcription factors
which lead to the downstream activation of various genes
involved in cell growth, differentiation, and survival [7].
These proteins exist as inactive monomers in the cyto-
plasm and become activated upon tyrosine phosphoryla-
tion. This phosphorylation event allows the STAT
molecules to form homodimers or heterodimers with
other activated STAT family members via its Src-homol-
ogy 2 (SH2) domain [8]. This dimer can then enter the
nucleus and activate transcription of various genes [9,10].
There have been seven mammalian STAT genes identified
to date [8,11]. The STAT3 protein is one of the major
members of this family that has been widely implicated in
numerous cancers [7,12]. Activation of STAT3 can lead to
cell-cycle progression, anti-apoptotic effects, proangio-
genesis, immune evasion, and tumor invasion and metas-
tasis [5,7]. These characteristics incorporate many of the
hallmarks of cancer [13]. In addition, STAT3 has been
implicated in the activation of downstream cytokines,
including vascular endothelial growth factor (VEGF),
which may also contribute to tumorigenesis [14].
Constitutive activation of STAT3 has been reported to be
sufficient to induce tumor formation in a range of human
cancers [12,15]. In addition, constitutively activated
STAT3 is frequently found in breast cancer cell lines and
patients with advanced breast disease, but is absent in
normal breast epithelial cells [16-18]. In particular, the
phosphorylated form of STAT3 at tyrosine residue 705
(Y705) is frequently found elevated within breast carcino-
mas [16]. Receptor-mediated activation of STAT proteins,
especially of STAT3 and STAT5, has been found to occur
both  in vitro and  in vivo in breast carcinogenesis [19].
Therefore, understanding the events leading to STAT3 acti-
vation will provide critical insight for treating and pre-
venting breast tumorigenesis.
The tumor microenvironment, or how tumor cells cross-
talk with other components in their surroundings, is a
vital feature of emerging cancer research. Paracrine signal-
ing within the microenvironment is important for regula-
tion of such characteristics as proliferation,
differentiation, and apoptosis [20]. The stroma also plays
a role in promoting angiogenesis, and altering the extra-
cellular matrix, as well as increasing inflammatory cell
recruitment to the area [21-23]. Fibroblasts are a signifi-
cant component of the stroma and have been identified to
have an active role in tumorigenesis, including the regula-
tion of breast cancer cell growth [24-26].
Recent research has demonstrated that activated STAT3
plays an important role in the cross-talk between cancer
cells and immune cells [27]. However, little has been
known about the activation of STAT3 in regards to the
other components within the tumor microenvironment,
including the interaction between tumor cells and sur-
rounding fibroblasts and epithelial cells.
Our laboratory is examining the effects of paracrine sign-
aling from breast cancer cells and breast fibroblasts with
increased phosphorylated STAT3 (p-STAT3) levels on
tumor progression. We show here that soluble factors
released from breast cell lines with high levels of STAT3
phosphorylation are sufficient to confer increased p-
STAT3 levels in recipient breast cell lines with low activa-
tion of this protein. This activation occurs through the
JAK/STAT3 signaling pathway, and mediates phenotypic
changes in the treated cells, including enhanced cell pro-
liferation and transformation of the cells to increase pro-
duction of cytokines, which may promote tumor
formation. Importantly, we noticed a correlation between
increased levels of p-STAT3 and Interleukin-6 (IL-6) pro-
duction from cells with constitutively active p-STAT3, and
found that IL-6 is one of the major factors contributing to
the paracrine activation of STAT3 in breast cell lines with-
out upregulated p-STAT3. Understanding how IL-6 and
other soluble factors are involved in this paracrine activa-
tion of STAT3 via the tumor microenvironment may pro-
vide new therapeutic insight to treat breast carcinomas
and other cancers with elevated p-STAT3 and IL-6 levels.BMC Cancer 2008, 8:302 http://www.biomedcentral.com/1471-2407/8/302
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Methods
Cell Culture and co-culture
MDA-MB-453, MDA-MB-468, MDA-MB-231 human
breast cancer cell lines and MCF-10A mammary epithelial
cells were purchased from ATCC. The breast cancer associ-
ated fibroblasts were provided by Dr. Tim Huang at the
Ohio State University Medical Center, which were derived
from breast cancer patients and the fibroblastic character-
istics were confirmed by the presence of their hallmark
antigens: vimentin and prolyl-4-hydroxylase (Data not
shown). Human breast cancer associated fibroblasts,
MDA-MB-453, MDA-MB-468, and MDA-MB-231 breast
cancer cell lines were maintained in 10% fetal bovine
serum (FBS) (Invitrogen), Dulbecco's Modification of
Eagle's Medium (DMEM), 1× with 4.5 g/L, L-glutamine, &
sodium pyruvate (Mediatech) with 1% Penicillin/Strepto-
mycin (P/S). MCF-10A mammary epithelial cell line was
grown in Ham's F12 media (Mediatech) with 5 μg/ml
insulin, 1 μg/ml hydrocortisone, 10 μg/ml epidermal
growth factor (EGF), 100 μg/ml cholera toxin, 5% FBS,
and 1% P/S. MDA-MB-453 cells were seeded in 6-well
plates and MDA-MB-468 cells were grown on top of 0.22
μM filter inserts to block physical contact between two dif-
ferent cell lines. MDA-MB-453 cells were co-cultured with
the MDA-MB-468 cells in 5% FBS, 1× DMEM for 4 days
after which the MDA-MB-453 cell lysates were collected
for Western blot analysis.
Conditioned Media
MDA-MB-468 or MDA-MB-231 cell lines were grown in
two, T-75 flasks. Breast fibroblasts were grown in four, 10-
cm plates. At 70% confluency, the cells were refed with
2% FBS, 1× DMEM media for 48 hours. The conditioned
media that was in the presence of p-STAT3-cell lines
(MDA-MB-468, MDA-MB-231 or breast fibroblasts) was
filtered (0.22 μM) to remove any cellular debris. The con-
ditioned media containing soluble factors secreted from a
p-STAT3-positive cell line was then used to treat MDA-
MB-453 or MCF-10A cells in 10-cm plates for various time
periods between 0.5 and 24 hours. MDA-MB-453 and
MCF-10A cell lysates were collected at their designated
time points for Western blot analysis.
Western blot analysis
For MDA-MB-453, 100 μg of total protein, or for MCF-
10A, 60 μg of total protein, from their respective cell
lysates were subjected to SDS polyacrylamide gel electro-
phoresis (PAGE) and transferred to PVDF membrane.
Membranes were blotted with phospho-specific STAT3
antibody (Tyrosine 705; #9131 Cell Signaling Tech. [Bev-
erly, MA]), which does not cross react with any other STAT
protien; phospho-specific STAT3 antibody (Serine 727;
#9134S Cell Signaling Tech. [Beverly, MA]), phospho-
independent STAT3 antibody (#9132 Cell Signaling
Tech.); phospho-specific AKT antibody (Serine 473;
#9271S Cell Signaling Tech. [Beverly, MA]); phospho-spe-
cific JAK1 antibody (Tyrosine 1022/1023; #3331 Cell Sig-
naling Tech. [Beverly, MA]), which may cross react with p-
JAK2; phospho-specific JAK2 antibody (Tyrosine 1007/
1008; #07-123 Upstate Biotech. [Temecula, CA]), which
does not cross react with any other protein; Cyclin D1
antibody (#2922 Cell Signaling Tech. [Beverly, MA]); and
GAPDH antibody (MAB374 Chemicon International, Inc.
[Temecula, CA]). β-Actin antibody (A 1978 SIGMA [St.
Louis, MO]) was used in Fig. 1B.
Antibody neutralization
0.22 μM filtered conditioned media (for IL-6, LIF, and
GAPDH neutralization) or adherent cells (for gp130
receptor neutralization) were treated with 4 μg/mL of
antibody (IL-6: MAB206 R&D Systems [Minneapolis,
MN]; LIF: AF-250-NA R&D Systems [Minneapolis, MN];
GAPDH: MAB374 Chemicon International, Inc; gp130:
MAB228 R&D Systems) for one hour on a slow rotor. The
conditioned media was left at 25°C during this incuba-
tion, while adherent cell lines were kept in a CO2 incuba-
tor at 37°C.
MTT Cell proliferation Assay
MCF-10A cells were seeded in 96-well plates (6000 cells/
well) in Ham's F12 media with the additives as described
above. After 24 hours, cells were washed and media was
replaced with 2% FBS, 1× DMEM. The following day,
MCF-10A cells were treated with MDA-MB-231 condi-
tioned media for various time points. MDA-MB-231 con-
dition media was made at a concentration of 5 × 106 cells/
20 ml of 2% FBS, 1× DMEM media for 48 hours. At the
end of each time point, 25 μl of MTT (Thiazolyl Blue
Tetrazolium Bromide: M5655, SIGMA) was added to each
well of the plate and incubated for 3.5 hours. After this,
100 μl of N,N-dimethylformamide (D4551, SIGMA) sol-
ubilization solution was added to each well. Plates were
left at room temperature overnight to allow complete lysis
of cells, and read at 450 nm the following day.
ELISA analysis
For Fig. 2A and Fig 2B: The cells were grown in 10-cm
plates until they had reached 75–80% confluency. Their
media was then replaced with DMEM supplemented with
2% FBS. These cells were then incubated at 37°C for an
additional 24 hours, whereupon their media was col-
lected, filter-sterilized, aliquoted, and stored at -80°C. For
Fig. 3, cells were grown in 6-well plates until they reached
75–80% confluency. Their media was then replaced with
DMEM supplemented with 2% FBS for 24 hours. The cells
were then treated with MDA-MB-231 cells' conditioned
media for 24, 48, or 96 hours. After this treatment, the
MCF-10A cells were washed and the media was replaced
with DMEM supplemented with 2% FBS. The cells were
then allowed to secrete their own cytokines for 24 hours,BMC Cancer 2008, 8:302 http://www.biomedcentral.com/1471-2407/8/302
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after which the media was collected, filter-sterilized, aliq-
uoted, and stored at -80°C. Secretion of IL-6 and IL-10
was quantified with ELISA kits obtained from Diaclone
(catalog #950.030.096, and 950.060.096, respectively,
[Stamford, CT]); VEGF secretion was monitored with an
ELISA kit from R&D Systems (catalog #DVE00, [Minneap-
olis, MN]). Each assay was performed per the manufac-
turer's instructions. Samples were assayed in triplicate.
Error bars represent +/- one standard deviation. For Fig.
2C: The cells were plated in triplicate at a concentration of
30,000 cells/well in 2% FBS, 1× DMEM in a 96-well plate.
Cells were grown for 48 hours, the media was removed,
filtered, and secretion of IL-6 was assayed using a human
IL-6 ELISA kit obtained from Diaclone (catalog
#950.030.096). The manufacturer's protocol was also
used for this assay.
RT-PCR analysis
MCF-10A cells were grown to 80% confluency in six-well
plates and then switched to DMEM supplemented with
2% FBS for 24 hours. The media was then replaced with
conditioned media from MDA-MB-231 or plain 2% FBS
DMEM for the listed times, after which RNA was extracted
with the Qiagen RNeasy kit (Qiagen, Valencia, CA) and
Soluble factor(s) secreted by MDA-MB-231, MDA-MB-468, and breast cancer associated fibroblasts are sufficient to amplify p- STAT3 (Y705) levels in MDA-MB-453 and MCF-10A Figure 1
Soluble factor(s) secreted by MDA-MB-231, MDA-MB-468, and breast cancer associated fibroblasts are suffi-
cient to amplify p-STAT3 (Y705) levels in MDA-MB-453 and MCF-10A. A. MDA-MB-453 cells were co-cultured with 
MDA-MB-468 cells for 120 hours. B. MCF-10A cells were treated with MDA-MB-468 conditioned media for 6 and 24 hours. C. 
MCF-10A cells were treated with MDA-MB-231 conditioned media for 0.5 hours. D. MDA-MB-453 cells were treated with 
MDA-MB-231 conditioned media for various time points between 0.5 and 24 hours. E. MCF-10A cells were treated with MDA-
MB-231 conditioned media for 1, 24, and 48 hours. F. MDA-MB-453 cells were treated with conditioned media from breast 
cancer associated fibroblasts for 0.5 hours. 453: MDA-MB-453; 468: MDA-MB-468; 231: MDA-MB-231; BCF: breast cancer 
associated fibroblasts; No Tx: no treatment; CM: conditioned media; hr: hour.
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stored at -80°C. Sample RNA was reverse transcribed
using Omniscript RT (Qiagen), and 2 μl of the cDNA
products were used to carry out non-quantitative RT-PCR.
Primers for human IL-6 were 5'-TACCCCCAGGAGAA-
GATTCC-3' (forward) and 5'-TTTCAGCCATCTTT-
GGAAGG-3' (reverse). Primers for GAPDH were 5'-
ATGGGGAAGGTGAAGGTCG-3' (forward) and 5'-
GGGGTCATTGATGGCAACAATA-3' (reverse). PCR
amplifications were performed as follows: 5 min at 94°C
followed by 30 cycles of (30 sec at 94°C, 30 sec at 55°C,
30 sec at 72°C) and a final extension at 72°C for 5 min.
The PCR products were then run on 2% agarose gels,
stained with ethidium bromide and visualized under UV
light.
Results
Soluble Factor(s) Secreted by MDA-MB-231, MDA-MB-
468, and Breast Cancer Associated Fibroblasts are 
Sufficient to Amplify p-STAT3 (Y705) Levels within MDA-
MB-453 and MCF-10A Breast Epithelial Cells
Since the role of the tumor microenvironment on STAT3
activation is not well understood, it was of interest to
examine the effects of paracrine signaling from breast can-
cer cells containing constitutively activated STAT3 (high
levels of p-STAT3) on breast cancer cells without constitu-
tively activated STAT3. MDA-MB-453, an estrogen recep-
tor alpha negative (ERα-) breast cancer cell line with
undetectable levels of p-STAT3 (Y705) was co-cultured
with MDA-MB-468, an ERα- breast cancer cell line with
Secretion of VEGF, IL-10, and IL-6 cytokines by various breast cell lines Figure 2
Secretion of VEGF, IL-10, and IL-6 cytokines by various breast cell lines. A. VEGF secretion by breast cell lines after 
24 hours. VEGF production does not correlate with p-STAT3 levels. B. IL-10 secretion by breast cell lines after 24 hours. IL-10 
production does not correlate with p-STAT3 levels. C. IL-6 secretion by breast cell lines after 48 hours. p-STAT3-positive cell 
lines secrete high levels of IL-6 and cell lines that do not express constitutive p-STAT3 have low levels of IL-6 secretion. Cell 
lines that do not express constitutive p-STAT3: MDA-MB-453 and MCF-10A; p-STAT3-positive cells: MDA-MB-468, MDA-
MB-231, and breast cancer associated fibroblasts (BCF).
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increased levels of p-STAT3. Soluble factors secreted from
the MDA-MB-468 cell line were sufficient to increase
STAT3 phosphorylation in MDA-MB-453 after five days of
growth in co-culture (Fig. 1A). To determine if this was a
phenomena only observed with MDA-MB-453, we treated
an immortalized, non-cancerous breast epithelial cell
line, MCF-10A, which expresses undetectable levels of p-
STAT3 (Y705), with media conditioned in the presence of
MDA-MB-468 cells for 24 hours. This conditioned media,
containing soluble factors from MDA-MB-468 cells, was
also sufficient to increase p-STAT3 in MCF-10A cells after
6 and 24 hours of treatment (Fig. 1B).
Further experiments were performed to support these
results. Conditioned media from an aggressive ERα-
breast cancer cell line with high p-STAT3 (Y705), MDA-
MB-231, was used to treat MCF-10A and MDA-MB-453
cell lines. Similar results were obtained, as the soluble fac-
tors secreted by MDA-MB-231 cells in this media also
induces an increase of p-STAT3 in both MCF-10A and
MDA-MB-453 cell lines (Fig. 1C, 1D, and 1E). Increased
levels of p-STAT3 were detectable as early as 30 minutes
after conditioned media treatment, persisting through at
least 24 to 48 hours (Fig. 1D and 1E).
Additionally, we used breast cancer associated fibroblasts
(BCF) with high p-STAT3 levels to treat MDA-MB-453
cells, demonstrating that soluble factors from BCF could
also induce STAT3 in MDA-MB-453 cells as early as 30
minutes (Fig. 1F). Furthermore, serially diluting the con-
Soluble factor(s) from MDA-MB-231 conditioned media were able to confer increased growth rates in MCF-10A Figure 3
Soluble factor(s) from MDA-MB-231 conditioned media were able to confer increased growth rates in MCF-
10A. A. MCF-10A cells were treated with MDA-MB-231 conditioned media and analyzed by MTT assay for cell viability. B. 
MCF-10A cells were treated with MDA-MB-231 conditioned media and/or 5 μM JSI-124. C. MCF-10A cells were treated with 
MDA-MB-231 conditioned media for varying amounts of time. Cell viability was analyzed by MTT assay. 231: MDA-MB-231; No 
Tx: no treatment; CM: conditioned media.
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ditioned media in fresh media before treatment of cells
demonstrated a proportional decline of p-STAT3 signal
(data not shown). This suggests that the increase in p-
STAT3 levels is directly correlated with the soluble factors
contained within the conditioned media. Phosphoryla-
tion of STAT3 at the tyrosine residue is necessary for
STAT3 activation [28]. There is also another phosphoryla-
tion site at the Serine 727 residue in the transactivation
domain of STAT3, which may lead to full activation of
STAT3, although serine phosphorylation has no influence
on STAT3's ability to bind DNA [29]. We did not see any
difference in phosphorylation of the Serine 727 residue
after conditioned media treatment (data not shown). In
addition, we assayed for phosphorylated AKT (p-AKT) at
Serine 473 (S473) after treatment of MCF-10A with MDA-
MB-468 cells' conditioned media; however, no elevation
of p-AKT (S473) was observed under these same condi-
tions (data not shown).
Activation of STAT3 Occurs through the JAK/STAT3 
Signaling Pathway
There are multiple ways in which STAT proteins can be
phosphorylated, including via Src or JAK non-receptor
tyrosine kinases, or via growth factors such as epidermal
growth factor (EGF) and platelet-derived growth factor
(PDGF) [30]. Therefore, it was important to identify
through which pathway this paracrine activation occurs.
JSI-124 (Cucurbitacin I) is a highly specific inhibitor to
the JAK/STAT3 pathway [31]. Pre-treating MCF-10A cells
with 10 μM of JSI-124 for one hour prior to MDA-MB-468
cells' conditioned media treatment was sufficient to abol-
ish the elevated levels of p-STAT3 (Y705) (Fig. 4A). Simi-
lar results were also obtained using the conditioned
media derived from MDA-MB-231 cells (Fig. 4B). A differ-
ent recipient, the MDA-MB-453 breast cell line, also
responded to JSI-124 upon conditioned media treatment
in a manner similar to MCF-10A (Fig. 4C). We also looked
at the levels of p-JAK1 and p-JAK2 after treatment with
conditioned media to see which JAK was responsible for
the induction of p-STAT3. We did not find a difference in
the levels of p-JAK1; however, we did see an increase in the
level of p-JAK2 which corresponded to increased p-STAT3
levels. Taken together, these data suggest that this para-
crine signaling occurs through the JAK/STAT3 signaling
pathway and is mediated by the soluble factor(s) in the
conditioned media. Nonetheless, other pathways may
still play a role and need to be explored.
Activation of STAT3 occurs through the JAK/STAT3 signaling pathway Figure 4
Activation of STAT3 occurs through the JAK/STAT3 signaling pathway. A. MCF-10A cells were treated with MDA-
MB-468 conditioned media for 0.5 hours. Treatment with 10 μM JSI-124 one hour prior to treatment with conditioned media 
reduced STAT3 activation. B. MCF-10A cells were treated with MDA-MB-231 conditioned media for 0.5 hours. Treatment 
with 10 μM JSI-124 one hour prior to treatment with conditioned media reduced STAT3 activation. C. MDA-MB-453 cells 
were treated with MDA-MB-231 conditioned media for 0.5 hours. Treatment with 10 μM JSI-124 one hour prior to treatment 
with conditioned media reduced STAT3 activation. 468: MDA-MB-468; 231: MDA-MB-231; 453: MDA-MB-453; No Tx: no 
treatment; CM: conditioned media.
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p-STAT3-positive Cell Lines Secrete High Levels of IL-6 
while p-STAT3-negative Cell Lines have Low Levels of IL-6 
Secretion
We next attempted to determine which soluble factors in
the conditioned media were responsible for this increase
in p-STAT3. We performed ELISA analysis for various
cytokines secreted from our cells of interest. We were
interested in examining production levels of VEGF, Inter-
leukin-10 (IL-10), and IL-6, as they have been reported as
activators as well as downstream targets of STAT3 [27]. It
was of significance to determine if our breast cancer epi-
thelial cell lines and associated fibroblasts could secrete
these factors, and whether these may be the paracrine acti-
vators of STAT3 observed in our experiments.
ELISA analysis for the secretion of VEGF showed that
while some p-STAT3-positive cell lines, namely MDA-MB-
468 and MDA-MB-231, had moderate production of
VEGF, MDA-MB-453 cells, which do not express constitu-
tively active STAT3, also had elevated levels of VEGF secre-
tion In addition, BCF had lower levels of VEGF secretion
(Fig. 2A). Therefore, VEGF secretion does not correlate
with the p-STAT3 status in these cells. Analysis of IL-10
secretion showed considerably low levels of production
(ranging between 3.31 and 5.31 pg/mL, Fig. 2B) in all cell
lines examined regardless their p-STAT3 status, and was
thus excluded from further studies. While no correlation
between high levels of p-STAT3 and the secretion of VEGF
or IL-10 was observed (Fig. 2A and 2B), high levels of IL-
6 secretion were seen in p-STAT3-positive cell lines: MDA-
MB-231, MDA-MB-468, and BCF (Fig. 2C). Moreover,
MCF-10A and MDA-MB-453 breast cell lines that do not
express constitutively active STAT3, had low or negligible
secretion of IL-6 (Fig. 2C). ELISA arrays for multiple
cytokines were also performed to compare the difference
in secretion of cytokines between MDA-MB-231 and
MCF10A. These also confirmed MDA-MB-231 breast can-
cer cells secrete much higher levels of IL-6 than immortal-
ized MCF-10A breast cells (data not shown). Once we had
singled out IL-6 as the soluble factor that may be respon-
sible for the paracrine activation of STAT3, we decided to
treat cells that do not express constitutively active STAT3,
MCF-10A and MDA-MB-453, with recombinant human
IL-6 and look at the effects on STAT3. We found that the
addition of IL-6 caused an increase in the levels of p-
STAT3 in both cells lines after just 30 minutes of treatment
(Fig. 5A and 5B). Immunohistochemical analysis pub-
lished in a recent paper by Berishaj et al also revealed a
strong positive correlation between the expression of IL-6
and the phosphorylation status of STAT3 [32]. These
observations suggest that IL-6 is an important soluble fac-
tor in the conditioned media which may lead to the para-
crine activation of STAT3 in breast cancer.
Inhibition of IL-6 or gp130 can Block the Elevation of p-
STAT3 (Y705) in MDA-MB-453 cells
Since IL-6 secretion correlates with high p-STAT3 levels, it
was important to determine whether blocking IL-6 would
be sufficient to inhibit the increase in p-STAT3 seen after
conditioned media treatment. IL-6 antibody was added to
the MDA-MB-231 conditioned media in order to bind
and neutralize IL-6 prior to treating MDA-MB-453 cells.
Neutralizing IL-6 was sufficient to block activation of
STAT3 (Fig. 6A). In addition, gp130 antibody was added
Addition of IL-6 is sufficient to increase levels of p-STAT3 in MDA-MB-453 and MCF-10A cell lines Figure 5
Addition of IL-6 is sufficient to increase levels of p-STAT3 in MDA-MB-453 and MCF-10A cell lines. A. MDA-MB-
453 cells were treated with 50 ng/ml IL-6 for 30 minutes. B. MCF-10A cells were treated with 25 ng/ml IL-6 for 30 minutes.
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to MDA-MB-453 cells to bind the gp130 component of
the IL-6 receptor prior to conditioned media treatment.
This was also able to block the increase of p-STAT3 (Fig.
6A). These results were consistent when repeated with
fibroblasts' conditioned media on MDA-MB-453 cells
(Fig. 6B). Together, these results suggest that IL-6 plays a
major role in the paracrine activation of STAT3 in breast
epithelial cells.
Soluble Factor(s) Released from MDA-MB-231 Confer 
Accelerated Cell Proliferation in MCF-10A cells
Since elevated p-STAT3 levels were observed in MCF-10A
cells after treatment with conditioned media, we next
examined if this phenomena renders a transformed phe-
notype in MCF-10A, a non-cancerous breast epithelial cell
line. Using MTT Assay, we demonstrated that soluble fac-
tors from MDA-MB-231 cells conferred amplified cell pro-
liferation in MCF-10A cells compared to no treatment
(Fig. 3A). To determine whether this increased cell prolif-
eration is in fact mediated through the JAK/STAT3 path-
way, we used JSI-124 in our MTT assays to see if we could
block the enhanced growth. Interestingly, the inhibitor
was able to significantly restrain the accelerated cell prolif-
eration of MCF-10A cells treated with MDA-MB-231 con-
ditioned media (Fig. 3B). Moreover, the conditioned
media-treated cells showed increased sensitivity to JSI-124
over untreated cells. This suggests that after cells become
dependent on an activated STAT3 pathway for survival or
Inhibition of IL-6 or gp130 is sufficient to block increased levels of p-STAT3 (Y705) in MDA-MB-453 Figure 6
Inhibition of IL-6 or gp130 is sufficient to block increased levels of p-STAT3 (Y705) in MDA-MB-453. A. MDA-MB-231 condi-
tioned media was subjected to 4 μg/ml IL-6, gp130, or GAPDH antibody neutralization. This neutralized conditioned media was 
then used to treat MDA-MB-453 cells for 0.5 hours. B. BCF conditioned media was subjected to 4 μg/ml IL-6, gp130, or 
GAPDH antibody neutralization. This neutralized conditioned media was then used to treat MDA-MB-453 cells for 0.5 hours. 
453: MDA-MB-453; 231: MDA-MB-231; BCF: breast cancer associated fibroblasts; No Tx: no treatment; CM: conditioned 
media.
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growth, shutting this pathway down selectively inhibits
cell viability. Past research has showed similar cytoxicity
using a dominant negative STAT3 and STAT3 inhibitors in
cervical cancer cell lines expressing increased p-STAT3
[33]. This shows promise for targeting STAT3 in cancer
patients with the use of a JAK/STAT inhibitor, as these
results suggest reduced toxicity to normal cells without the
enhanced STAT3 activation.
We decided to look at one of the downstream targets of
STAT3, Cyclin D1, which is involved in the G1/S cell cycle
transition, to explain the increased cell proliferation [6].
After treating MCF-10A cells with MDA-MB-231 condi-
tioned media for varying amounts of time we looked to
see if there was any change in cyclin D1 levels. We found
increased levels after both 24 and 48 hours of treatment
(Fig. 3C). This could explain the increased cell prolifera-
tion seen.
Soluble Factor(s) from MDA-MB-231 cells Stimulate MCF-
10A cells to Increase Production of IL-6
In this study, we found a positive correlation between IL-
6 production and STAT3 activation in p-STAT3-positive
cell lines. In addition, soluble factors, particularly those
within the IL-6 family of cytokines, are important in para-
crine activation of STAT3. Moreover, activation of STAT3
has been implicated in the upregulation of various
cytokines, including IL-6 [27]. Therefore, we were inter-
ested in determining whether paracrine activation of
STAT3 could also induce the conditioned media-treated
cells to increase their production of IL-6. Since MCF-10A
cells do not express constitutively activated STAT3 and
secrete low levels of IL-6, we examined the possibility that
soluble factors released from MDA-MB-231 breast cancer
cell lines may stimulate MCF-10A cells to produce differ-
ent cytokines, including the IL-6 family cytokines and oth-
ers. We treated MCF-10A cells with conditioned media
from MDA-MB-231 breast cancer cells, which produce
considerable levels of IL-6. After various time points, the
conditioned media was extensively washed away, and
MCF-10A cells were allowed to produce their own IL-6 for
24 hours. IL-6 secretion was analyzed by ELISA. Our
results suggest that soluble factors within the MDA-MB-
231 conditioned media are also sufficient to stimulate an
increase in IL-6 levels of approximately 2-fold (Fig. 7A) in
MCF-10A cells compared to untreated MCF-10A cells (96
hour treatment). To confirm these results, we performed
non-quantitative RT-PCR using cDNA reverse transcribed
from the RNA of MCF-10A cells treated with MDA-MB-
231 conditioned media or DMEM alone. Bands corre-
sponding to the IL-6 PCR product are readily detected in
the MCF-10A samples treated with conditioned media,
but are otherwise absent in the untreated controls (Fig.
7B). This is the first report showing that the secretion of
IL-6 can be induced by paracrine signaling in non-trans-
formed MCF-10A mammary epithelial cells.
Discussion
Our laboratory was interested in determining how breast
cells with increased levels of p-STAT3 could influence
their surroundings. Our findings show that soluble factors
from breast cell lines with high levels of STAT3 activation
are sufficient to confer increased p-STAT3 levels in other
cell lines with low activation of this protein. We used sev-
eral different cell lines with constitutive p-STAT3, includ-
ing breast cancer epithelial cells and fibroblasts. In
addition, paracrine activation was seen in both cancerous
and non-tumorigenic human mammary epithelial cells.
We showed that this activation was dose dependent on
soluble factors in the conditioned media, as diluting the
conditioned media treatment also resulted in a parallel
reduction of the p-STAT3 (Y705) signal. Therefore, it is
evident that p-STAT3-positive breast cancer epithelial cell
lines and breast cancer associated fibroblasts secrete solu-
ble factors, which can influence cells in a paracrine fash-
ion.
The time frame for how this paracrine activation of STAT3
occurs was also interesting. We observed that increased
STAT3 phosphorylation can occur in as little as 30 min-
utes, and this increased STAT3 phosphorylation can per-
sist for at least 48 hours. After performing time point
assays, we found that the phosphorylation level increased
greatly at 30 minutes and reached a steady elevation at 6,
8, and 24 hours later but declined at 48 hours, although
not to untreated levels. (Fig. 1D, Fig. 4D, and data not
shown).
We next examined which factors were causing this
increase in p-STAT3 activation. After performing ELISA
analysis for various suspects, we found that an increase in
p-STAT3 expression correlated with increased production
of IL-6 in our breast cell lines. A growing body of evidence
indicates a prominent and often contradictory role for IL-
6 in breast cancer, and numerous reports have shown it to
function in both a tumor-promoting and tumor-counter-
acting capacity [34]. These inconsistencies underscore IL-
6's nature as a pleiotropic cytokine. IL-6 has been demon-
strated as a potent activator of the JAK/STAT3 pathway
[35], and has been shown to act in an autocrine manner
to induce STAT3 to contribute to the pathogenesis of lung
cancer [14]. In addition, mesenchymal stem cells, which
are a major component of the fibroblast cell population in
bone marrow, have recently been identified to secrete IL-
6 in a paracrine fashion to enhance growth in ERα+ breast
cancer cell lines [36]. Since bone is the primary site for
metastasis in breast cancer patients, these results suggest
IL-6 may be a major factor contributing to tumor growth
and metastasis. The data presented in this manuscriptBMC Cancer 2008, 8:302 http://www.biomedcentral.com/1471-2407/8/302
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demonstrate that IL-6 is a paracrine activator of STAT3 in
ERα- breast cell lines as well. All of this data highlight IL-
6 as a positive feed-back mechanism in STAT3 activation.
STAT3 increases production of IL-6, which can further
stimulate and prolong STAT3 activation in breast cancer
epithelial cells in an autocrine as well as a paracrine fash-
ion, as shown here in this manuscript. In support of IL-6
as one of the major paracrine factors leading to the activa-
Soluble factor(s) from MDA-MB-231 stimulate MCF-10A to increase production of IL-6 Figure 7
Soluble factor(s) from MDA-MB-231 stimulate MCF-10A to increase production of IL-6. A. MCF-10A cells were 
treated with MDA-MB-231 conditioned media for 24, 48, or 96 hours. After this treatment time, MCF-10A cells were washed 
and allowed to produce their own cytokines for 24 hours, after which ELISA analysis was performed to assay for IL-6 secre-
tion. For the 0 hour treatment, conditioned media was added, but was washed away immediately and collected for analysis. 
This was done to show that any soluble factors from the MDA-MB-231 conditioned media were washed away and were not 
contaminating our results. For untreated MCF-10A cells, the cells were mock-treated with fresh 2% FBS, 1× DMEM instead. B. 
To confirm that soluble factors from the MDA-MB-231 conditioned media were inducing MCF-10A to produce IL-6, RNA col-
lected from these cells and used to perform non-quantitative RT-PCR. RNA from MDA-MB-231 was used as a positive control. 
231: MDA-MB-231; No Tx: no treatment; CM: conditioned media.
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tion of STAT3 in breast cells, we neutralized IL-6 from
conditioned media or blocked a major component of its
receptor (gp130). Blocking IL-6 or gp130 abolished the
increased p-STAT3 seen in the MDA-MB-453 cell line
treated with conditioned media. In a recent article by Ber-
ishaj, Gao, and Ahmed et al., sequestration of IL-6 from
MDA-MB-468 cells' conditioned media or blocking the
gp130 receptor was sufficient to reduce conditioned
media-induced STAT3 activation in MCF-10A cells [32].
Their findings and ours support each other, and further
establish that IL-6 is a major contributing factor to the
paracrine activation of STAT3 in breast cell lines.
However, the expected results were not observed when we
treated MCF-10A cells with MDA-MB-231 cells' condi-
tioned media. Neutralizing IL-6 in the conditioned media
did not seem to significantly reduce p-STAT3. Neverthe-
less, blocking its major receptor, gp130, was sufficient to
abolish this signal (data not shown). This could be due to
one of several major possibilities: First, this could reflect
that IL-6 is required at much lower concentrations to acti-
vate p-STAT3 in MCF-10A cells, and therefore, we were
probably unable to completely block all of the IL-6 from
the MDA-MB-231 cells' conditioned media using neutral-
izing IL-6 antibody. Second, IL-6 might not be the only
soluble factor, which leads to the major activation of p-
STAT3 in MCF-10A cells. It is also possible that another
un-identified cytokine within the IL-6 family which sig-
nals through the gp130 receptor is also involved in para-
crine activation of STAT3 in MCF-10A cells. We have yet
to identify this other soluble factor that may be acting
through the gp130 receptor. We have tried neutralizing
LIF using LIF neutralizing antibody. However, neutraliz-
ing LIF in the conditioned media did not seem to reduce
p-STAT3 (data not shown). The third possibility is that
there is a combinatory effect between IL-6 and another
factor, which leads to STAT3 activation. Further analysis
should be made in this area to determine all the soluble
factors, which should be targeted to sufficiently block
paracrine activation of STAT3 in MCF-10A cells.
Next, it was important to determine if the cells acquired a
transformed phenotype associated with this increase in p-
STAT3 protein level. First, we examined the ability of sol-
uble factors secreted by a p-STAT3-constitutively active
cell line to upregulate cell proliferation of a non-cancer-
ous cell line (MCF-10A). Soluble factors were able to
cause an increase in cell proliferation rate in MCF-10A
cells. We also saw increased levels of cyclin D1 which may
explain the increase in cell proliferation. Since cyclin D1 is
a downstream target of STAT3 it makes since that
increased activity of STAT3 would lead to greater cell
growth. This would play an important role in the transi-
tion of a normal cell into a cancer cell. There was also an
increase in cell proliferation observed in MCF-10A cells
and T-47D ERα+ breast cancer cells after treatment with
BCF conditioned media (data not shown). When using
MDA-MB-468 breast cancer cells as the source of condi-
tioned media, we observed very limited enhanced growth
as compared to the growth seen in MCF-10A cells treated
with MDA-MB-231 conditioned media (data not shown).
However, this correlates well with the greater level of IL-6
production from MDA-MB-231 breast cancer cells com-
pared to MDA-MB-468 breast cancer cells. If IL-6 is the
major factor contributing to this enhanced growth, then
the much higher production of IL-6 by MDA-MB-231
breast cancer cells versus MDA-MB-468 breast cancer cells
(Figure 2C) would account for the lack in enhanced cell
proliferation effect in MDA-MB-468 breast cancer cells.
When repeating this experiment with MDA-MB-453
treated with MDA-MB-231 cells' conditioned media, how-
ever, we were unable to observe an increase in growth
phenotype. We attribute this to the fact that MDA-MB-453
is already a breast cancer cell line with increased growth
rates compared to MCF-10A cells, and therefore did not
acquire the phenotype of increased cell growth by MDA-
MB-231 cells' conditioned media. However, since acti-
vated STAT3 may lead to several other carcinogenic mech-
anisms, such as resistance to apoptosis, angiogenesis, and
tumor invasion [6], it is possible that paracrine activation
of STAT3 in MDA-MB-453 cells may lead to those signifi-
cant cancerous phenotypes. Therefore, it will be interest-
ing to study additional phenotypic effects in the future so
that we can fully understand how paracrine activation of
STAT3 affects breast cancer.
Another useful phenotype which may correlate with
STAT3 activation is chemoresistance. As with many
human diseases, breast cancer patients may acquire chem-
oresistance to their drug therapies. Taxanes, including
docetaxel, are often used for the treatment of breast can-
cer. However, chemoresistance or an incomplete response
against this class of drugs is often acquired in patients
[37]. Understanding which cellular mechanisms allow
cancer tissues to acquire chemoresistance will help us to
overcome this challenge.
In 2002, Real et al. described resistance to chemotherapy
via overexpression of the anti-apoptotic protein Bcl-2 in
metastatic breast cancer cells, which correlated with the
activation of the STAT3 pathway [38]. As anti-apoptotic
proteins have been found to be downstream targets of
STAT3 activation in breast cancer [39], and chemoresist-
ance in breast cancer cells has been linked to inhibition of
apoptosis [40], it is likely that STAT3 activation may play
an important role in chemoresistance in breast cancer. In
fact, overexpression of activated STAT3 is found in most
paclitaxel-resistant ovarian cancer cells, suggesting that
this overexpression may lead to the resulting chemoresist-
ant phenotype [41]. Increased levels of IL-6 have beenBMC Cancer 2008, 8:302 http://www.biomedcentral.com/1471-2407/8/302
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shown to increase breast cancer cells' resistance to doxoru-
bicin [42]. Our future experiments will look at a role of
paracrine activated STAT3 as a source of chemoresistance
in MDA-MB-453, MCF-10A, as well as other breast cell
lines.
Our results further demonstrated that MCF-10A cells
treated with conditioned media from MDA-MB-231
breast cancer cells can allow MCF-10A cells to produce
and secrete their own IL-6. IL-6 can enhance motility of
breast cancer cells [43] and autocrine production of IL-6
causes multidrug resistance in breast cancer cells [44]. Fur-
ther, IL-6 is a potent growth factor for ER-α positive
human breast cancer [36]. Our lab also found that after
treatment of MCF-10A cells with MDA-MB-231 condi-
tioned media, MCF-10A elevated their production of the
Interleukin-8 (IL-8) cytokine by 5-fold (supplemental
data not shown). Research has shown that IL-8 can mod-
ulate growth and invasiveness of breast cancer cells and
the expression of IL-8 by human breast cancer cells corre-
lates with bone metastasis in vivo [45,46]. While IL-8 is
not a member of the IL-6 family, it is evident that para-
crine signaling from breast cancer cell lines is important in
transformation.
Conclusion
We have shown that STAT3 can be activated through para-
crine signaling in breast epithelial cells and this activation
occurs through the JAK/STAT3 signaling pathway. IL-6
production is correlated with this increase in p-STAT3 and
IL-6 appears to be one of the major factors contributing to
paracrine activation. This paracrine activated STAT3 is
important as it leads to transformed phenotypes, such as
increased cell proliferation and an increase in production
of IL-6. This suggests that IL-6 paracrine activation of
STAT3 contributes to the process of breast tumorigenesis.
Understanding which soluble factors are involved in this
paracrine signaling and how these factors lead to STAT3
activation via the tumor microenvironment will provide
new therapeutic targets for breast carcinomas and other
cancers with elevated p-STAT3 levels.
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